Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of olaparib monotherapy in relapsed small cell lung cancer with homologous recombination pathway alterations
KCT0002276Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Aug 2016; status: recruiting.
02
Drugs
olaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0002276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002276.